Skip to main content

AB 1320 — California

California Affordable Drug Manufacturing Act of 2020: opioid antagonists.

Failed / died 20252026 session Assembly

This page lists STATE bills only. Open States, our source for this data, tracks state legislatures -- it has no visibility into city councils, county commissions or school boards. We don't yet have a free, storable source for local measures; see the About page for why.

Summary

Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) or its departments to enter into partnerships, in consultation with other state departments as necessary, to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. For purposes of implementing these provisions, existing law authorizes CHHSA and its departments, including the Department of Health Care Access and Information, to enter into exclusive or nonexclusive contracts on a bid or negotiated bases. Existing law exempts these contracts entered into by CHHSA and its departments from the review or approval of any division of the Department of General Services as well as from provisions pertaining to bidding and awarding of state contracts.

This bill would prohibit a state agency from awarding a contract, pursuant to the above provisions, on a noncompetitive basis for the purchase or acquisition of an opioid antagonist, as defined, with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic. The bill would make a contract void and unenforceable for a violation of this provision and apply those provisions retroactively to contracts entered into before January 1, 2026.

Official abstract, as published by the legislature.

  • AB 1320 is a bill in the California Assembly, 20252026 session, introduced February 21, 2025.
  • Current status: failed / died.
  • Most recent action (February 2, 2026): From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.
  • 2 recorded votes; the most recent, on April 29, 2025, passed 16-0.
  • Subjects: CaliforniaAffordableDrugManufacturingActof2020, opioidantagonists.

Contact your legislator about this bill

Bill text & documents

Sponsors

Cosponsors (1): Patterson

History

  1. Introduced, completed
  2. Passed Assembly (stopped), where this bill stopped
  3. Passed Senate, not reached yet
  4. Sent to Governor, not reached yet
  5. Signed into law, not reached yet
  1. Assembly Introduced. To print. Milestone
  2. Assembly From printer. May be heard in committee March 24.
  3. Assembly Read first time.
  4. Assembly Referred to Com. on HEALTH.
  5. Assembly In committee: Set, first hearing. Failed passage. Reconsideration granted.

    Reconsideration.: 16 yes 0 no Passed, 100% yes

    Do pass and be re-referred to the Committee on [Appropriations]: 4 yes 3 no, 9 other Failed, 57% yes

  6. Assembly Died pursuant to Art. IV, Sec. 10(c) of the Constitution. Milestone
  7. Assembly From committee: Filed with the Chief Clerk pursuant to Joint Rule 56. Milestone Latest

Source: Open States. Last checked November 13, 2026. How we keep this accurate ›